Epicutaneous Immunotherapy for Egg Allergy

Phase 2

Recruiting

• Conditions: Egg allergy; Egg allergy, epicutaneous immunotherapy

• Registration Number: JPRN-jRCTs031200307
• Lead Sponsor: Iwai Fumiko

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-01-18
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 63

Inclusion Criteria

1 Immediate-type of hen's egg allergy
2 specific IgE to egg white at 3.5 UA/mL or more
3 Participants who have threshold of egg protein cumulative dose of 150mg or less

Exclusion Criteria

1 Participants with severe symptoms in oral food challenge for hen's egg allergy
2 Participants who have had only gastrointestinal symptoms as allergic symptoms
3 Poorly controlled participants with bronchial asthma and/or atopic dermatitis
4 Participants receiving immunotherapy for other food allergens during this trial

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of participants who pass oral food challenge to 150mg of egg protein at 24 weeks

Secondary Outcome Measures

Name	Time	Method
1 Proportion of participants who pass oral food challenge to 500 mg of egg protein at 24 or 48 weeks<br>2 Proportion of participants who pass oral food challenge to 150 mg of egg protein at 48 weeks<br>3 Adverse event<br>4 Changes in immunological markers